The Nasdaq staged a more than 2 percent rally back from the brink of correction territory Tuesday in the biggest one day turnaround in five years.» Read More
Amgen fools us: One of my favorite exercises at the Breaking News Desk is to figure out whether something is news, and how it might move the stock involved. This morning, a headline moved regarding Amgen’s anemia drug Aranesp. I’m not a pharmaceutical expert -- that’s why we have reporter Mike Huckman -- but since it involved a very large company and a drug I’d actually heard of, we knew it was news. Here’s where it got interesting...
Shares of Amgen surged after the biotech giant said that its anemia drug Aranesp showed no difference in risk of death compared with a placebo in a closely watched study of the medicine in small-cell lung cancer patients.
Stocks closed mixed but the Dow Jones Industrial Average inched up to another record as investors awaited key quarterly reports after the bell. "You still have some pretty important earnings coming out that are going to set the tone," said Adam Tracy, director of listed trading at Thomas Weisel Partners.
Earnings blowouts and encouraging drug trials were some of the catalysts behind Thursday's most actively traded stocks.
It was a volatile day for the celebs. Champion poker player Chris Moneymaker holds onto the first spot despite his $90K loss on Syntel but actor Jonathan Tucker takes over the #2 spot. Meanwhile, Willie Garson falls into 4th, allowing Stephen Collins to gain 3rd place. Johnny Bench falls from 6th to 8th. One of the stocks for Chris M., CBST, is also a favorite of Parker Robinson in our non-celeb trading. Both are "banking" on it paying off.
Champion poker player Chris Moneymaker widens his lead in first place to more than $150K with the sale of Adtran which was up 6.16% Tuesday--as actor Willie Garson lost over $20k on Seagate Technology--which was down 1.73% Tuesday. And actor Stephen Collins decided to take time off from his acting career--to make more buys and sells than everyone on Wall Street (I'm making this last sentence up--but as you will see, it's not that far off!).
Cramer's got the call on Bank of America, Jones Soda, AIG and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Healthcare giant Johnson & Johnson reported quarterly earnings above Wall Street estimates and raised 2007 earnings guidance, sending shares up almost 3%.
World champ poker player Chris Moneymaker retains his lead in Trading With The Stars--though actor Willie Garson climbed back into second. Only about $10,000 separates the two. The balance between the two will hang on Monday's (today's) performance of Moneymaker's purchase of Rio Narcea Mines and Willie's buy of Mattel. AND Johnny Bench fought his way...
The National Kidney Foundation said on Thursday it plans to cut its recommended target for hemoglobin levels in kidney disease patients -- a move that could hurt sales of lucrative anemia drugs that boost hemoglobin but have come under scrutiny over safety concerns.
Genentech said first-quarter earnings surged 68% and reported quarterly earnings above expectations amid solid growth for blockbuster cancer drug Avastin. But sales of Lucentis, a treatment for age-related blindness, came up short.
Amgen, theworld's largest biotechnology company, said after U.S. markets closed Tuesday that it appointed Robert Bradway as chief financial officer.
Willie Garson proves himself as a celeb to beat, and holds the lead for the 3rd straight day in Trading With The Stars. There was a "flip flop" (no politicians here) of sorts as actor Stephen Collins replaced champion poker player Chris Moneymaker in the second spot--and Chris is in third. All the other celebs are holding their previous places. Actor James Cromwell is showing...
Here's a look at where celeb Judy Gold stands in Trading with the Stars--as chronicled by the crew on "Morning Call," the show she's playing for. She's in 6th place, but DYING to move up a spot or two. Willie Garson still leads the pack after what can only be described as a "tremendous" move up the ranks. (see Timothy Sykes' blog post today).
Here's our update on "Trading With The Stars." Willie proves himself as not another flash in the pan, and maintains the #1 spot two day's in a row. (and just like Willie--almost- Johnny Bench holds onto 7th place!) Interesting note: all of our celeb portfolios are above the $1 million benchmark. Congrats to all for that!!
Despite a volatile first quarter, stocks aren't much above where they were at the beginning of the year. But even if the major averages aren't showing big gains, smart investors know where to look for growth opportuntities.
The Lightning Round is back, and the callers are especially revved up. Cramer's got the word on Akamai, Cheesecake Factory and a lot more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Stocks closed slightly higher Friday, finishing a week with gains of more than 3% in major market indices. "I like to see this pretty tight trading range; the fact that we've been able to hold on to these gains is healthy," Craig Columbus, chief market strategist at Advanced Equities Asset Management, told CNBC.com.
Sun Micro, Vodafone, Six Flags and more: Cramer tells you to buy or sell.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Amgen's stock fell sharply after the company said it had discontinued a key clinical trial of its drug Vectibix in combination with other drugs as an initial treatment for colon cancer. The report helped boost shares of other drugmakers such as ImClone Systems, which makes a competing drug Erbitux.